JP2024521788A - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP2024521788A
JP2024521788A JP2023572798A JP2023572798A JP2024521788A JP 2024521788 A JP2024521788 A JP 2024521788A JP 2023572798 A JP2023572798 A JP 2023572798A JP 2023572798 A JP2023572798 A JP 2023572798A JP 2024521788 A JP2024521788 A JP 2024521788A
Authority
JP
Japan
Prior art keywords
inhibitor
kras
pharma
amino
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521788A5 (https=
Inventor
ヘリング，ジェイコブ
ケッチャム，ジョン・マイケル
クヘア，シルピ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024521788A publication Critical patent/JP2024521788A/ja
Publication of JP2024521788A5 publication Critical patent/JP2024521788A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023572798A 2021-05-27 2022-05-24 併用療法 Pending JP2024521788A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194140P 2021-05-27 2021-05-27
US63/194,140 2021-05-27
US202263329056P 2022-04-08 2022-04-08
US63/329,056 2022-04-08
PCT/US2022/030697 WO2022251193A1 (en) 2021-05-27 2022-05-24 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024521788A true JP2024521788A (ja) 2024-06-04
JP2024521788A5 JP2024521788A5 (https=) 2025-04-01

Family

ID=84229070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572798A Pending JP2024521788A (ja) 2021-05-27 2022-05-24 併用療法

Country Status (5)

Country Link
US (2) US12280055B2 (https=)
EP (1) EP4346826A4 (https=)
JP (1) JP2024521788A (https=)
TW (1) TW202313050A (https=)
WO (1) WO2022251193A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188383A4 (en) * 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
WO2022271679A1 (en) * 2021-06-21 2022-12-29 Mirati Therapeutics, Inc. Sos1 inhibitors
AU2023250314A1 (en) * 2022-04-08 2024-10-03 Mirati Therapeutics, Inc. Combination therapies comprising a sos1 inhibitor and a mek inhibitor
CN120112284A (zh) * 2022-08-19 2025-06-06 米拉蒂治疗股份有限公司 阿达格拉西布固体药物组合物
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1838675A1 (en) 2004-11-24 2007-10-03 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060211073A1 (en) 2005-03-21 2006-09-21 May Earl W Assay for B-Raf activity based on intrinsic MEK ATPase activity
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US20070172843A1 (en) 2005-09-12 2007-07-26 Conrad Susan E MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
WO2007071951A1 (en) 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (ja) 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
EA200802050A1 (ru) 2006-04-19 2009-04-28 Лаборатуар Сероно Са Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
US7772233B2 (en) 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
GB0625691D0 (en) 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
ES2426096T3 (es) 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
CN102448938A (zh) 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
CN102666512B (zh) 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
US20120238599A1 (en) 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors
FI3702351T3 (fi) 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
EP2920144A4 (en) 2012-11-15 2016-06-29 Univ Holy Ghost Duquesne CARBOXYLIC ACID TESTER PRODRUG HEMMER FROM MEK
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10118911B2 (en) 2015-03-27 2018-11-06 Jiangsu Hengrui Medicine Co., Ltd. P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
WO2016188472A1 (zh) 2015-05-28 2016-12-01 正大天晴药业集团股份有限公司 Mek抑制剂的药物组合物及其制备方法
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
BR112021012057A2 (pt) * 2018-12-21 2021-10-19 Revolution Medicines, Inc. Compostos que participam de ligação cooperativa e usos dos mesmos
CN115315424A (zh) 2019-10-15 2022-11-08 拜耳公司 2-甲基-氮杂-喹唑啉
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
CN115942936A (zh) * 2020-06-24 2023-04-07 勃林格殷格翰国际有限公司 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法
CR20230402A (es) * 2021-01-19 2023-11-21 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer

Also Published As

Publication number Publication date
WO2022251193A1 (en) 2022-12-01
TW202313050A (zh) 2023-04-01
US12280055B2 (en) 2025-04-22
US20220395507A1 (en) 2022-12-15
US20250032497A1 (en) 2025-01-30
EP4346826A1 (en) 2024-04-10
EP4346826A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
JP7546549B2 (ja) 組み合わせ療法
JP7546548B2 (ja) 組み合わせ療法
JP2024521788A (ja) 併用療法
JP2025000632A (ja) 組み合わせ療法
KR20210113587A (ko) 병용 요법
JP2022500384A (ja) 組み合わせ療法
JP2025000629A (ja) 組み合わせ療法
JP2024540839A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
JP2024537139A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
JP2025512999A (ja) Ｓｏｓ１阻害剤及びｅｇｆｒ阻害剤を含む併用療法
WO2022165142A1 (en) Combination therapies
US20250186453A1 (en) Combination therapies comprising a sos1 inhibitor and a mek inhibitor
HK40101229A (zh) 组合疗法
CN117615762A (zh) 组合疗法
TW202428280A (zh) 組合療法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
EA048458B1 (ru) Способы комбинированной терапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421